We are live on ! Find out more
ICM

Indaba Capital Management Portfolio holdings

AUM $33.8M
1-Year Est. Return 33.83%
This Fund
S&P 500
This Quarter Est. Return
+0.47%
1 Year Est. Return
+33.83%
3 Year Est. Return
+66.66%
5 Year Est. Return
+44.49%
10 Year Est. Return
+91.89%
AUM
$153M
AUM Growth
-$21M
Cap. Flow
-$96.4M
Cap. Flow %
-62.95%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$3M
2
OBDC icon
Blue Owl Capital
OBDC
+$1.37M
3
LAB icon
Standard BioTools
LAB
+$201K

Sector Composition

Rank Sector Weight
1 Technology 37.26%
2 Healthcare 13.03%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONTF
1
DELISTED
ON24
ONTF
$30.3M 19.77%
4,240,256
– –
SNPO
2
DELISTED
Snap One Holdings Corp. Common Stock
SNPO
$26.8M 17.5%
3,109,281
– –
LAB icon
3
Standard BioTools
LAB
$326M
$20M 13.03%
7,363,064
-83,165
-1% -$201K
HLLY.WS
4
DELISTED
Holley Inc Warrants
HLLY.WS
$234K 0.15%
669,159
– –
OBDC icon
5
Blue Owl Capital
OBDC
$5.35B
– –
-92,568
Closed -$1.37M
MACK
6
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-223,459
Closed -$3M

Similar funds

APM
Advanced Portfolio Management New York $32.8M AUM 6.64% 1-Year Est. Return
CI
Centerstone Investors New York $31.8M AUM 32.46% 1-Year Est. Return
MIG
Meketa Investment Group Westwood, Massachusetts $29.6M AUM 2.01% 1-Year Est. Return
SPA
Sherbrooke Park Advisers White Plains, New York $38.7M AUM 5.29% 1-Year Est. Return
SM
Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SWM
Stark Wealth Management Bethlehem, Pennsylvania $26.6M AUM 23.19% 1-Year Est. Return

Indaba Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Indaba Capital Management held 9 positions worth $153M, down 12% from $174M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Indaba Capital Management withdrew a net $96.4M in Q1 2024, closing 2 positions and reducing 1 holding. Its most notable exit was Merrimack Pharmaceuticals, Inc., an estimated $3M position sold in full.

By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.

  • Indaba Capital Management's biggest Q1 2024 reduction was Standard BioTools, cutting an estimated $201K.
  • Indaba Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q1 2024, selling an estimated $3M.
  • Indaba Capital Management's ten largest holdings make up 100% of its $153M portfolio in Q1 2024.
  • Indaba Capital Management opened 0 new positions and closed 2 in Q1 2024.
  • Indaba Capital Management's portfolio value fell 12% quarter-over-quarter to $153M.

Based on Indaba Capital Management's 13F filing for Q1 2024, filed 15 May 2024.